10-K: Astria Therapeutics Reports Full Year 2023 Results, Advances Clinical Programs

Astria Therapeutics, a biopharmaceutical company, released its full year 2023 results, highlighting progress in its clinical development programs for allergic and immunological diseases.

Summary

• Astria Therapeutics is focused on developing novel therapeutics for allergic and immunological diseases.
• Their lead product candidate, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for hereditary angioedema (HAE).
• STAR-0215 has shown potential for long-acting, effective attack prevention for HAE with dosing every three or six months.
• The company initiated a Phase 1a clinical trial of STAR-0215 in August 2022, with final results shared in February 2024, showing it was well-tolerated with a long half-life of up to 109 days.
• A Phase 1b/2 trial called ALPHA-STAR is underway, evaluating safety, tolerability, and HAE attack rate in patients, with initial proof-of-concept data expected in the first quarter of 2024.
• If ALPHA-STAR results are positive, Astria plans to progress STAR-0215 directly to a Phase 3 pivotal trial, anticipated to start in the first quarter of 2025.
• Their second product candidate, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for atopic dermatitis (AD).
• Astria plans to submit an IND for STAR-0310 by the end of 2024 and initiate a Phase 1a clinical trial in healthy subjects in the first quarter of 2025.
• The company estimates the HAE market was greater than $2 billion in 2022 and could grow to $4.5 billion by 2027.
• The moderate-to-severe AD treatment market was approximately $7 billion in 2022 and could grow to $26 billion by 2030.
• Astria reported a net loss of $72.9 million for the year ended December 31, 2023, compared to a net loss of $51.8 million in 2022.
• As of December 31, 2023, Astria had $246.5 million in cash, cash equivalents, and short-term investments, which they expect will fund operations into mid-2027.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there is progress in clinical development and a large market opportunity, the company is still in the early stages, faces significant risks, and is incurring substantial losses. The need for additional funding and the competitive landscape temper the positive aspects.

Positives

• STAR-0215 has shown a favorable safety profile and long half-life, supporting its potential for infrequent dosing.
• The ALPHA-STAR trial is designed to provide data on both three and six month administration of STAR-0215.
• Astria has a clear plan to advance STAR-0215 directly to a Phase 3 trial if Phase 1b/2 results are positive.
• STAR-0310 has the potential to address a broad range of T cells involved in AD pathology.
• The company has a strong cash position to fund operations into mid-2027.

Negatives

• Astria has incurred significant losses since inception and expects to continue incurring losses for the foreseeable future.
• The company has never generated any revenue from product sales and may never be profitable.
• Clinical trials are costly, time-consuming, and inherently risky, with no guarantee of success.
• The company faces substantial competition from other pharmaceutical and biotechnology companies.
• The price of Astria's common stock is likely to continue to be highly volatile.

Risks

• The company is entirely dependent on the success of STAR-0215 and STAR-0310.
• Interim data from clinical trials may change as more data becomes available.
• The company will need substantial additional funding, and failure to raise capital could force delays or elimination of programs.
• Clinical trials may fail to demonstrate safety and efficacy.
• Product candidates may cause adverse events or undesirable side effects.
• The company relies on third parties for manufacturing and clinical trials, which could harm the business if they do not perform satisfactorily.
• The company may not be able to obtain and maintain sufficient patent protection.
• The price of the company's common stock is likely to continue to be highly volatile.

Future Outlook

The company expects to continue to incur significant expenses and operating losses for the foreseeable future. They plan to advance STAR-0215 and STAR-0310 through clinical trials and seek regulatory approvals. The company also plans to expand its pipeline and explore additional indications for its product candidates.

Management Comments

• The goal for STAR-0215 is to develop a best-in-class monoclonal antibody inhibitor of plasma kallikrein able to provide long-acting, effective attack prevention for HAE.
• Our vision for STAR-0215 is to become the first-choice preventative treatment for HAE with administration every three or six months with the goal of normalizing the lives of people living with HAE.
• Our goal for STAR-0310 is to reduce disease activity, relapse rate, and treatment burden for patients with moderate and severe AD in order to help normalize their lives.

Industry Context

The document highlights the competitive landscape in both the HAE and AD markets, noting the presence of established therapies and other product candidates in development. This underscores the need for Astria to demonstrate a differentiated profile for its product candidates to achieve commercial success.

Comparison to Industry Standards

• The document mentions several competitors in the HAE market, including CSL Behring, Takeda, Pharming, and BioCryst, which have approved therapies like BERINERT, FIRAZYR, KALBITOR, RUCONEST, CINRYZE, HAEGARDA, TAKHZYRO, and ORLADEYO. Astria's STAR-0215 aims to compete with TAKHZYRO as a monoclonal antibody inhibitor of plasma kallikrein.
• In the AD market, the document notes competition from biologics like DUPIXENT and ADBRY, as well as oral JAK inhibitors like RINVOQ and CIBINQO. Astria's STAR-0310 aims to differentiate itself by targeting OX40 and offering a longer duration of action.
• The document also mentions other companies with product candidates in development for AD, including Amgen (rocatinlimab), Sanofi (amlitelimab), Eli Lilly (lebrikizumab), and Galderma (nemolizumab), indicating a highly competitive landscape.

Stakeholder Impact

• Shareholders face the risk of dilution from future capital raises and potential losses due to stock price volatility.
• Employees are subject to the risks associated with a development-stage company, including potential job insecurity.
• Patients with HAE and AD may benefit from new treatment options if the company's product candidates are successful.
• Suppliers and contract manufacturers are subject to the risks associated with the company's financial stability and development progress.
• Creditors face the risk of non-payment if the company is unable to secure additional funding or generate revenue.

Next Steps

• Report initial proof-of-concept data in HAE patients from the ALPHA-STAR trial in the first quarter of 2024.
• Progress STAR-0215 directly to a Phase 3 pivotal trial, anticipated to start in the first quarter of 2025, assuming positive data from the Phase 1b/2 trial.
• Submit an IND for STAR-0310 by the end of 2024.
• Initiate a Phase 1a clinical trial of STAR-0310 in healthy subjects in the first quarter of 2025.
• Report initial results from the Phase 1a clinical trial of STAR-0310 in the third quarter of 2025.
• Initiate a Phase 1b clinical trial of STAR-0310 in patients with AD in the second half of 2025.
• Report results from the Phase 1b clinical trial of STAR-0310 in the second quarter of 2026.

Key Dates

Keywords

Hereditary Angioedema, Atopic Dermatitis, Monoclonal Antibody, Plasma Kallikrein, OX40 Antagonist, Clinical Trials, Biopharmaceutical, Immunological Diseases, Allergic Diseases, Drug Development